ANTIHYPERTENSIVE THERAPY IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE
Article Sidebar
Main Article Content
Аннотация:
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which have nephroprotective effects, are first-line drugs (FL) for treatment of arterial hypertension (AH) in patients with chronic kidney disease (CKD). However, these groups of drugs have a number of contraindications, certain adverse drug reactions, unwanted drug interactions and therefore cannot be prescribed in all AH patients with CKD. Therefore, real clinical practice studies are needed to assess the real frequency of nephroprotective drugs prescription, especially in the elderly.
Article Details
Как цитировать:
Библиографические ссылки:
Thomas B, Matsushita K, Abate KH, Al-Aly Z, Arnlov J, Asayama K, et al. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28(7):2167–79.
Ali S, Dave N, Virani SS, Navaneethan SD. Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr Atheroscler Rep. 2019;21(9):32.
Jumanazarov, S., Jabbarov, O., Umarova, Z., Tursunova, L., & Mirzayeva, G. (2022). Factors affecting platelet hemostasis and resistance to curantil in patients with chronic kidney disease.
Mirzaeva, G. P. (2023). Evaluation of the effectiveness of antioxidants on the functional state of the kidneys in patients with diabetic nephropathy.